Rossi Ernesto
Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma.
Recenti Prog Med. 2020 Dec;111(12):48e-53e. doi: 10.1701/3509.34976.
The treatment of cutaneous melanoma harboring BRAF mutation has been greatly enriched. BRAF/MEK inhibitors can improve the outcome of patients with this disease. On the other hand, immunotherapy can also be effective. A focus on the role of immune checkpoint inhibitors in advanced melanoma with BRAF mutation has been performed.
携带BRAF突变的皮肤黑色素瘤的治疗方法已得到极大丰富。BRAF/MEK抑制剂可改善此类疾病患者的治疗结果。另一方面，免疫疗法也可能有效。目前已对免疫检查点抑制剂在BRAF突变的晚期黑色素瘤中的作用进行了研究。
